AT-Rich Interactive Domain-Containing Protein (ARID): A Potential Drug Target and Biomarker

Target Name: AT-Rich interactive domain-containing protein

NCBI ID: P47632

AT-Rich interactive domain-containing protein

Other Name(s): ARID

AT-Rich Interactive Domain-Containing Protein (ARID): A Potential Drug Target and Biomarker

AT-rich interactive domain-containing protein (ARID) is a protein that plays a crucial role in various cellular processes. It is a subtype of the non-spectral domain protein (NSD), which is a family of proteins known for their unique topological features. The NSDs are characterized by the presence of an AT-rich domain, which consists of a stretch of amino acids that is rich in aromatic amino acids, as well as a C-terminal region that is involved in protein-protein interactions and other cellular processes.

ARID is a protein that is expressed in various tissues and cells of the human body, including the brain, heart, and liver. It is involved in various cellular processes, including cell signaling, DNA replication, and protein synthesis. The ARID protein has also been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug Target Potential

ARID has the potential to be a drug target due to its unique structure and various cellular processes. The ARID protein is known to have multiple interacts with various cellular components, including other proteins and nucleic acids. This suggests that targeting ARID could be an effective way to treat various diseases.

One potential mechanism by which ARID could be targeted is through its role in cell signaling. The ARID protein has been shown to play a role in various signaling pathways, including the Wnt signaling pathway. This pathway is involved in the development and maintenance of neural stem cells, and is a potential target for diseases that involve the regulation of neural stem cells.

Another potential mechanism by which ARID could be targeted is through its role in DNA replication. The ARID protein has been shown to play a role in the regulation of DNA replication, which is a critical process for the development and progression of cancer.

Biomarker Potential

In addition to its potential as a drug target, ARID also has the potential as a biomarker. The ARID protein is expressed in various tissues and cells of the human body, including the brain, heart, and liver. This makes it a potential marker for disease, including cancer, neurodegenerative diseases, and autoimmune disorders.

One potential use for ARID as a biomarker is its ability to be expressed and purified from various tissues and cells. This allows for the development of diagnostic tools that can detect ARID protein levels in a variety of biological samples, such as blood, urine, or tissue samples.

Conclusion

In conclusion, ARID is a protein that has the potential to be a drug target and biomarker. Its unique structure and various cellular processes make it an attractive target for researchers to investigate. Further studies are needed to determine the full potential of ARID as a drug and biomarker.

Protein Name: AT-Rich Interactive Domain-containing Protein (nonspecified Subtype)

The "AT-Rich interactive domain-containing protein Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AT-Rich interactive domain-containing protein comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets